Aurora Cannabis (ACB) Q1 2027 earnings review
The 'Reset Year' Begins: Margins Squeezed as Strategy Pivots
Aurora's Q1 2027 results delivered the exact pain management warned about last quarter. Total net revenue fell 9% YoY and 20% sequentially to $67.6M. The decline was driven by a brutal ~30% cut in Canadian medical reimbursement rates that slashed domestic sales, compounded by the strategic wind-down of the low-margin consumer segment. The silver lining is International Medical, which grew 17% YoY to $43.3M, now comprising 64% of total revenue. While Adjusted EBITDA compressed significantly to $3.4M (from $10.8M YoY), the balance sheet remains bulletproof with zero cannabis debt and a pending $46.4M cash unlock from an insurance program wind-up.
🐂 Bull Case
International Medical revenue is accelerating, up 17% YoY to $43.3M. Driven by strong demand in Germany, this high-margin segment is successfully replacing legacy domestic revenue.
The wind-up of the segregated cell insurance program will reclassify $46.4M from restricted cash to available cash. Combined with existing liquidity and zero cannabis debt, Aurora has unmatched capital flexibility in a constrained sector.
🐻 Bear Case
The ~30% cut to Canadian medical reimbursements is a permanent headwind. Medical adjusted gross margin decelerated from 69% to 61%, proving that even growth in Europe cannot entirely mask domestic pricing pressure.
The company burned $5.8M in Free Cash Flow this quarter, a stark reversal from the $6.8M generated a year ago. The transition year is proving expensive on a cash basis.
⚖️ Verdict: ⚪
Neutral. The quarter was undeniably ugly on the surface (declining revenue, shrinking EBITDA, negative FCF), but it was highly telegraphed. Management is executing a painful but necessary pivot away from low-margin segments to defend its EU-GMP moat. If International growth holds, the structural reset will pay off.
Key Themes
International Medical Expansion Accelerating
International Medical net revenue grew 17% YoY to $43.3M, driven heavily by increased patient demand in Germany following recent descheduling. International sales now represent an overwhelming 64% of total net revenue (up from 50% a year ago). The company is successfully leveraging its EU-GMP footprint to dominate consolidated, high-barrier markets abroad.
Canadian Reimbursement Cut Crushes Margins
The macroeconomic/regulatory impact of the April 1, 2026 change to the Canadian federal reimbursement program (VAC) hit hard. The ~30% cut to reimbursement rates drove a $7.0M YoY decline in Canadian medical revenue. More importantly, it caused the overall Medical adjusted gross margin to decelerate sharply from 69% to 61% YoY.
Safari Acquisition Secures Critical EU-GMP Supply
Aurora closed the $24.7M Safari Flower Company acquisition in April. This instantly adds 59,000 sq ft of EU-GMP certified indoor capacity in Ontario, dedicated to feeding the surging German and UK markets. Safari officially received its 3-year EU-GMP certification renewal in July, validating the deal's strategic intent to bypass European supply bottlenecks.
Proprietary Genetics Moat
Aurora continues to distance itself from pure cultivators by relying on a technology-driven genetics program. These proprietary cultivars provide up to 40% higher yields and significant disease resistance, which directly lowers cost per gram. This scientific consistency is a prerequisite for maintaining strict EU-GMP compliance and securing market share in Germany's heavily regulated medical landscape.
Free Cash Flow Turns Negative
Despite management pointing to a $3.4M improvement in the reported net loss (aided by favorable FX swings), the underlying cash generation tells a different story. Free Cash Flow reversed from a positive $6.8M a year ago to a negative $(5.8)M this quarter. Operating cash flow before working capital changes plunged to $(9.9)M from $2.1M YoY, exposing the true cash cost of the revenue decline.
Consumer Wind-Down Drag
The planned exit from the Canadian consumer market is proceeding, with revenue decelerating to just $2.1M (down from $7.9M YoY). However, adjusted gross margin in this segment collapsed to 20% (down from 33%) because the company is liquidating inventory at heavy discounts to clear the channel. This clearance strategy resulted in nearly $7.8M of inventory impairment charges hitting the cost of sales.
Massive Insurance Cash Unlock
A major balance sheet catalyst emerged post-quarter: the Board approved winding down the segregated cell self-insurance program. This action will reclassify $46.4M of restricted cash into unrestricted cash by Q3 FY2027, boosting their already healthy $69.3M cash pile by over 65%. This gives Aurora immense dry powder for opportunistic M&A.
Other KPIs
Stable YoY (compared to $36.1M in Q1 26). Aurora is successfully holding the line on overhead expenses despite integrating the Safari acquisition and dealing with international expansion costs. Management expects this run-rate to hold steady through the transition year.
Decelerating aggressively from $10.8M YoY and $9.2M in the prior quarter. The $8.3M drop in adjusted gross profit (due to the Canadian medical pricing cuts and consumer liquidation) fell straight to the bottom line, offset slightly by lower SG&A.
Improved slightly from $27.3 million at the end of FY2026. The company successfully sold through some previously written-down consumer inventory, though they still recognized $13.9M in fresh inventory impairments and fair value adjustments during the quarter.
Guidance
Reversing. Management expects revenue to grow sequentially from Q1's $67.6M floor. This implies the worst of the 'reset' shock (the sudden April 1st implementation of reimbursement cuts) is behind them, and Safari's integration combined with German growth will drag the top-line back up.
Reversing. After compressing to $3.4M in Q1, management expects Adjusted EBITDA to expand in Q2. This relies on the assumption that the heavy consumer inventory discounting will subside and high-margin European sales will comprise a larger mix of the total.
Key Questions
Safari Integration Ramp
With Safari's EU-GMP certification secured in July, how quickly can this facility reach full utilization, and what is the expected quarterly revenue contribution for the back half of FY2027?
Capital Allocation of Unlocked Cash
The wind-up of the segregated cell program frees up $46.4M in cash. Given the ATM is also available, is this capital earmarked for further cultivation M&A, downstream distribution acquisitions in Europe, or share buybacks?
Canadian Medical Margin Floor
Medical adjusted gross margins fell 800 basis points to 61% following the VAC reimbursement cut. Has this margin profile found its absolute floor, or should we expect further compression as legacy patients roll over to the new pricing scheme?
Germany Pricing Pressure
Management previously noted pricing pressure in Germany's value segment. As more competitors secure EU-GMP supply lines, are you seeing any of this pricing compression bleed into the core or premium segments where Aurora operates?